Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes

Type 1 Diabetes Clinical Trial

— SMILE  

Official title:

Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02733991
• Other study ID #: CEP311
• Status: Completed
• Phase: N/A
• Start date: December 2016
• Est. completion date: October 2018

Study information

• Verified date: January 2020
• Source: Medtronic Diabetes
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A premarket, international multicenter, prospective, open label, adaptive, randomized controlled study.

The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and SmartGuard™in preventing hypoglycemic events in comparison with continuous subcutaneous insulin infusion therapy in type 1 diabetes adults with an increased risk of hypoglycemia. The primary objective is to demonstrate a reduction in the mean number of hypoglycemic events when using the MiniMed™640G system with SmartGuard™ and the secondary objectives will aim at evaluating the difference in glycemic parameters and HbA1c.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 153
• Est. completion date: October 2018
• Est. primary completion date: October 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age 24-75 years old at time of screening.

• Diagnosed with Type 1 diabetes =10 years prior to screening.

• On pump therapy for = 6 months prior to screening.

• Not on Real Time continuous glucose monitoring for = 3 months prior to screening.

• HbA1c value =5.8% and =10.0% as assessed by local lab = 15 days prior to screening or performed at screening.

• A documented Severe Hypoglycemia event = 12 months prior to screening, OR Clarke score =4 assessed at time of screening, OR

• Gold score =4 assessed at time of screening.

• Subject is willing to sign and date informed consent, comply with all study procedures and wear all study devices as required during the study.

Exclusion Criteria:

• Untreated Addison's disease, thyroid disorder, growth hormone deficiency, hypopituitarism or definite gastroparesis, per investigator judgment.

• Subject is using Pramlintide (Symlin) SGLT2 inhibitor, GLP agonist at time of screening.

• Renal failure defined by creatinine clearance <30 ml/min, as assessed by local lab test = 3 months before screening or performed at screening at local lab.

• Hearing or vision impairment hindering perception of glucose display and alarms, or otherwise incapable of using the study devices, per investigator judgment.

• Current pregnancy or intention to conceive.

• Any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection).

• Alcohol or drug abuse, other than nicotine, per investigator judgment.

• Any other disease or condition that may preclude the patient from participating in the study, per investigator judgment.

• Legally incompetent, illiterate or vulnerable person.

Randomization Criteria:

• If subjects meet the above criteria, as well as all of the following criteria assessed at the end of the run-in period, they may continue to participate in the treatment period of the study:

• Subject has worn two weeks the sensor with transmitter during the run-in period.

• Subject has shown acceptable tolerance of sensor wear, per investigator judgment.

• Subject performed = 4 finger stick blood glucose measurements daily, as determined by CareLink™ Clinical data upload as the mean number of SMBG/day over the past 14 days (SMBG number / day = 3.5 rounds up to 4).

• Subject showed ability to comprehend the pump training and study procedures, per investigator judgment.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Device:
• MiniMed™640G and Suspend before low
All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON. Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase.
• MiniMed™640G
Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.

Locations

Country	Name	City	State
France	CHU de Besançon	Besançon
France	CHU Grenoble	Grenoble
France	APHM - La Conception	Marseille
France	CHU Montpellier - Hôpital Lapeyronie	Montpellier
Italy	Ospedale Papa Giovanni XXIII	Bergamo
Italy	Ospedale S. Raffaele	Milan
Italy	Ospedale S. Gionanni di Dio	Olbia
Netherlands	Groene Hart Ziekenhuis	Gouda
Netherlands	Maasstad Ziekenhuis	Rotterdam
Netherlands	UMC Utrecht	Utrecht
Netherlands	Isala	Zwolle
United Kingdom	Harrogate District Hospital	Harrogate	N. Yorkshire
United Kingdom	King's College London	London
United Kingdom	Manchester Diabetes Center	Manchester

Sponsors (1)

Lead Sponsor	Collaborator
Medtronic Diabetes

Countries where clinical trial is conducted

France,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Number of Sensor Glucose Hypoglycaemic Events Below or Equal to 55 mg/dL Per Patient/Week.		6 months
Secondary	Mean Time Spent of Sensor Glucose Values Below or Equal 55 mg/dL.		6 months
Secondary	Mean Time Spent of Sensor Glucose Values Within Range and Including 70-180 mg/dL.		6 months